Sharing about the development strategy of Vietnam's pharmaceutical industry to 2030, with a vision to 2045, Director of the Department of Drug Administration Vu Tuan Cuong said: Based on the assessment of the current situation and the identification of the limitations of Vietnam's pharmaceutical industry in the recent period, on October 9, 2023, the Prime Minister issued Decision 1165/QD-TTg in 2023 approving the National Strategy for the development of Vietnam's pharmaceutical industry to 2030 and a vision to 2045.
Accordingly, the goals set for the pharmaceutical industry in the coming period are the following: "...towards becoming a center for manufacturing/technology transfer of generic pharmaceuticals in the ASEAN region, striving to develop the domestic pharmaceutical industry to level 4 according to WHO classification".
Specific goals are identified:
By 2030: Domestically produced drugs strive to meet about 80% of usage demand and 70% of market value, produce 20% of raw material demand for domestic drug production, domestically produced vaccines meet 100% of demand for expanded immunization and 30% of demand for service immunization.
By 2045: Proactively produce specialized drugs, new drugs, original branded drugs, vaccines, biological products and pharmaceutical ingredients; have original branded drugs from domestic medicinal materials that are researched, produced and copyrighted. Strive for the total value of the pharmaceutical industry to contribute to GDP of over 20 billion USD.
To achieve the above objectives of the Pharmaceutical Industry Development Strategy, the Ministry of Health has developed and proposed priority areas for development and preferential policies to support investment in the development of the pharmaceutical industry to achieve the development objectives of the Pharmaceutical Industry Development Strategy, specifically:
In the Law amending the Law on Pharmacy passed by the National Assembly at the 8th session of the 15th National Assembly, the contents of Article 8 were amended. Incentive policies and investment support in the development of the pharmaceutical industry are as follows:
- Regulations on priority development areas to promote the development of the pharmaceutical industry according to development and integration requirements include:
+ Research and develop technology, produce or transfer technology to produce herbal medicines, traditional medicines from domestic herbal sources, pharmaceutical ingredients, new medicines, original branded medicines, rare medicines, the first domestically produced generic medicines, high-tech medicines, vaccines, biological products;
+ Research and development of gel sources, varieties, and medicinal herb growing areas:
- Supplementing the preferential policies to enjoy specific benefits according to the provisions of the Investment Law for the above fields as follows: Newly established investment projects (including the expansion of newly established projects) in the development of the pharmaceutical industry with a total investment capital of VND 3,000 billion or more, disbursing at least VND 1,000 billion within 03 years from the date of being granted the Investment Registration Certificate or approval of the investment policy.
- In addition, the Law on Pharmacy also supplements specialized policies to encourage development such as:
+ Priority and incentives in purchasing drugs from the state budget and other legal revenue sources of public health facilities; Priority in procedures and time for granting circulation registration certificates; Application of incentive and support mechanisms from the Funds supporting science and technology activities for drugs in priority development areas.
+ Combine state budget investment with mobilizing other resources for the development of the vaccine, biological, herbal and traditional medicine production industry, and medicines produced from domestic herbal sources; Support clinical trials, registration for circulation, and protection of intellectual property rights for traditional medicines and herbal medicines; protect confidentiality in the preparation, processing, and clinical trial data of traditional medicines.
